Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 11, 2024
Event: The Company announced the redemption of its outstanding 2.625% Convertible Senior Notes due 2026.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data disclosed relates to debt obligations:
- Debt Instrument: 2.625% Convertible Senior Notes due 2026.
- Aggregate Principal Amount Called: $26,350,000.
- Redemption Price: 100% of the principal amount plus accrued and unpaid interest to, but excluding, the Redemption Date.
- Settlement Method: The Company has elected to settle all conversions of Notes between the announcement and the Conversion Deadline in cash.
Material Changes
The filing reports a material change in the Company's capital structure through the decision to redeem all outstanding Convertible Senior Notes. This action reduces the Company's long-term debt obligations and eliminates the associated interest expense and conversion risk for the specified instrument.
Outlook, Risks, and Unusual Items
Redemption Timeline:
- Redemption Date: June 14, 2024.
- Conversion Deadline: June 13, 2024 (5:00 p.m. New York City time).
Investor Verification Checklist
- Verify the exact accrued interest amount payable on the $26,350,000 principal as of June 14, 2024.
- Confirm the Company's available cash or liquidity position to fund the full redemption and potential cash settlements of conversions.
- Review the attached Press Release (Exhibit 99.1) for additional strategic rationale regarding the debt repayment.
- Monitor subsequent filings for the official Notice of Redemption and confirmation of the transaction's completion.